GlassScriptPhysician profile
Ariel Perez Perez
NPI 1821416389
$119,929.43
in general payments reported to CMS, 2019-2025
29 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $109 · 2021: $125 · 2022: $1,006 · 2023: $46K · 2024: $25K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Food and Beverage: $6,771 · Travel and Lodging: $6,087 · Consulting Fee: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,420.00 |
| Food and Beverage | $6,771.35 |
| Travel and Lodging | $6,086.95 |
| Consulting Fee | $1,712.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $112,337.48 | 2022-2025 | Yescarta |
| Pfizer INC. | $1,080.31 | 2022-2025 | |
| Abbvie INC. | $761.10 | 2024-2025 | |
| Genzyme Corporation | $678.53 | 2024-2025 | |
| Janssen Biotech, INC. | $591.06 | 2024-2025 | Carvykti, Rybrevant, Talvey |
| Janssen Scientific Affairs, LLC | $588.75 | 2022-2025 | Tecvayli, Talvey, Carvykti |
| Celgene Corporation | $545.43 | 2019-2025 | Reblozyl, Opdivo |
| Genmab U.S., INC. | $537.55 | 2023-2025 | Epkinly |
| Sanofi-Aventis U.S. LLC | $367.92 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.06 | 2023-2024 | Reblozyl |
| Incyte Corporation | $226.24 | 2022-2024 | Monjuvi |
| Astellas Pharma US INC | $190.00 | 2019 | |
| Genentech USA, INC. | $174.51 | 2023-2024 | Columvi, Lunsumio, Polivy |
| Seagen INC. | $161.26 | 2022-2023 | |
| Johnson & Johnson Health Care Systems INC. | $145.65 | 2024 | Darzalex |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $132.48 | 2024 | Rezlidhia, Tavalisse |
| Novocure INC. | $125.00 | 2019 | |
| Gamida Cell INC. | $125.00 | 2025 | Omisirge |
| Beigene USA, INC. | $124.99 | 2021 | |
| Stemline Therapeutics INC. | $124.74 | 2024 | Elzonris |
| Lilly USA, LLC | $124.71 | 2023 | Jaypirca |
| Novo Nordisk INC | $121.60 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $109.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $102.24 | 2019 | |
| Adaptive Biotechnologies Corporation | $92.82 | 2022-2023 | Clonoseq |
| Biocompatibles, INC. | $35.33 | 2019 | |
| Sobi, INC | $28.62 | 2024 | |
| Beone Medicines USA, INC. | $27.08 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $22.63 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Perez Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.